Vivos Therapeutics Shares Quadruple on FDA Clearance of Sleep Apnea Treatment

By Dean Seal

Shares of Vivos Therapeutics Inc. rose fourfold to a high of $2.96 after the company's flagship oral appliance received regulatory clearance as a sleep apnea treatment.

The Littleton, Colo.-based medical technology company said Wednesday morning that the Food and Drug Administration has cleared Vivos' proprietary daytime-nighttime appliance for the treatment of mild-to-moderate obstructive sleep apnea.

The palatal expansion device is already Vivos' longest standing appliance with the widest use among Vivos-trained dentists, the company said.

After closing the market on Tuesday at 74 cents, Vivos shares surged to a high of $2.96 about an hour after trading opened Wednesday. They then slipped throughout the morning, leveling off at $2 by 1:30 p.m. EST.

Shares are still down 12% over the last 12 months.

Write to Dean Seal at [e-mail]

(END) Dow Jones Newswires

01-04-23 1354ET